Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

Rhea-AI Summary

Revive Therapeutics (OTCQB: RVVTF) has completed the first tranche of its private placement offering, raising $60,900 through the issuance of 2.9 million units at $0.021 per unit. Additionally, the company settled $67,400 in debt through the issuance of 3.2 million units at the same price.

Each unit consists of one common share and one warrant exercisable at $0.05 for 36 months. The company also issued 100,000 compensation options to an investment dealer. The proceeds will be used for working capital and trade payables, with securities subject to a hold period until December 9, 2025.

Positive

• Debt settlement of $67,400 preserves cash for operations
• Additional funding of $60,900 secured through private placement
• Warrants provide potential for future capital at $0.05 per share

Negative

• Significant dilution through issuance of over 6.1 million new units
• Low unit pricing at $0.021 indicates weak market position
• Additional dilution possible through compensation options and warrants

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.021 per Unit, for total gross proceeds to Revive of $60,900. Furthermore, the Company announces that it has settled an amount of $67,400 owing pursuant to an arm’s length note through the issuance of 3,209,523 Units, at a price of $0.021 per Unit, being the same issue price and security offered pursuant to the Offering.

Each Unit is comprised of one common share of the Company (a “Common Share”) and one Common Share purchase warrant (a “Warrant”). Each Warrant entitles the holder to acquire one Common Share at an exercise price of $0.05 for a period of 36 months following the date of issuance.

The gross proceeds from the Offering will be used by the Company for working capital and payment of certain trade payables.

The Company determined that it was desirable to settle the outstanding note payable through the issuance of securities in order to preserve the Company’s cash for ongoing operations.

In connection with the closing of the first tranche of the Offering, Revive issued an aggregate of 100,000 compensation options (each, a “Compensation Option”) to an arm’s length investment dealer involved in the Offering. Each Compensation Option entitles the dealer to purchase one unit of the Company (a “Compensation Unit”) at a price of $0.05 per Compensation Unit for a period of eighteen months following the date of issuance.

Each Compensation Unit is comprised of one Common Share (a “Compensation Share”) and one-half of a Common Share purchase warrant (a “Compensation Warrant”). Each whole Compensation Warrant entitles the holder to acquire one Compensation Share at an exercise price of $0.05 for a period of 36 months following the date of issuance.

All of the securities issued are subject to a hold period of four months and one day expiring on December 9, 2025.

About Revive Therapeutics Ltd.

Revive Therapeutics is a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs. Revive strategically prioritizes its drug development pipeline to leverage FDA regulatory incentives like Emergency Use Authorization, Orphan Drug, Fast Track, and Breakthrough Therapy designations, positioning for rapid advancement and market entry. Currently, our efforts are concentrated on unlocking the vast potential of Bucillamine for infectious diseases and medical countermeasures, including the pioneering treatment of nerve agent exposure. Furthermore, Revive is vigorously advancing our Psilocybin and molecular hydrogen therapeutic programs, exploring new frontiers in medical science. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank

Chief Executive Officer

Revive Therapeutics Ltd.

Tel: 1 888 901 0036

Email: mfrank@revivethera.com

Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider has reviewed or accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “may”, “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the Company’s cannabinoids, psychedelics and infectious diseases programs. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s management’s discussion and analysis for the three and nine months ended March 31, 2025 (“MD&A”), dated May 29, 2025, which is available on the Company’s profile at www.sedarplus.ca.

FAQ

What is the size and price of Revive Therapeutics' (RVVTF) private placement first tranche?

The first tranche consisted of 2.9 million units at $0.021 per unit, raising total gross proceeds of $60,900.

How much debt did Revive Therapeutics (RVVTF) settle in this announcement?

Revive settled $67,400 in debt through the issuance of 3,209,523 units at $0.021 per unit.

What are the terms of the warrants in RVVTF's private placement?

Each warrant entitles holders to acquire one common share at an exercise price of $0.05 for a period of 36 months following issuance.

When does the hold period expire for RVVTF's newly issued securities?

The securities are subject to a hold period of four months and one day, expiring on December 9, 2025.

How will Revive Therapeutics use the proceeds from this offering?

The proceeds will be used for working capital and payment of certain trade payables.